MDAT: Difference between revisions
Content deleted Content added
No edit summary |
Undid revision 365621060 by 82.24.103.156 (talk) |
||
| Line 19: | Line 19: | ||
}} |
}} |
||
'''6,7-Methylenedioxy-2-aminotetralin''' ('''MDAT''') is a [[drug]] developed in the 1990s by a team at [[Purdue University]] led by [[David E. Nichols]].<ref name="pmid1967651">{{cite journal | author = Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM | title = Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA) | journal = Journal of Medicinal Chemistry | volume = 33 | issue = 2 | pages = 703–10 | year = 1990 | month = February | pmid = 1967651 | doi = | url = }}</ref> It |
'''6,7-Methylenedioxy-2-aminotetralin''' ('''MDAT''') is a [[drug]] developed in the 1990s by a team at [[Purdue University]] led by [[David E. Nichols]].<ref name="pmid1967651">{{cite journal | author = Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM | title = Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA) | journal = Journal of Medicinal Chemistry | volume = 33 | issue = 2 | pages = 703–10 | year = 1990 | month = February | pmid = 1967651 | doi = | url = }}</ref> It appears to act as a [[serotonin releasing agent]] based on rodent drug discrimination assays comparing it to [[3,4-methylenedioxy-N-methylamphetamine|MDMA]], in which it fully substitutes for, and additionally lacks any kind of [[serotonergic]] [[neurotoxicity]].<ref name="pmid1967651">{{cite journal | author = Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM | title = Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA) | journal = Journal of Medicinal Chemistry | volume = 33 | issue = 2 | pages = 703–10 | year = 1990 | month = February | pmid = 1967651 | doi = | url = }}</ref> Hence, MDAT is a non-[[neurotoxic]], putative [[entactogen]] in humans. |
||
== See Also == |
== See Also == |
||
* [[2-Aminotetralin]] |
* [[2-Aminotetralin]] |
||
Revision as of 11:38, 2 June 2010
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H13NO2 |
| Molar mass | 191.223 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
6,7-Methylenedioxy-2-aminotetralin (MDAT) is a drug developed in the 1990s by a team at Purdue University led by David E. Nichols.[1] It appears to act as a serotonin releasing agent based on rodent drug discrimination assays comparing it to MDMA, in which it fully substitutes for, and additionally lacks any kind of serotonergic neurotoxicity.[1] Hence, MDAT is a non-neurotoxic, putative entactogen in humans.
See Also
References
- ^ a b Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM (1990). "Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry. 33 (2): 703–10. PMID 1967651.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link)